Clinical trial
A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)
NCT07184619 is registered in ClinicalTrials.gov with Newron Pharmaceuticals SPA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III, 12-week, Prospective, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multi-center Study to Determine the Efficacy, Safety, and Tolerability of a Dose of 15 mg Bid of Evenamide as add-on in Patients With Documented Treatment-resistant Schizophrenia, Which is Not Adequately Controlled by a Stable Therapeutic Dose of the Patient's Current Antipsychotic Medication(s)
- Lead sponsor
- Newron Pharmaceuticals SPA
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- January 23, 2026
- Completion date
- March 31, 2027
- Enrollment
- 400 (estimated)
- Sites
- 19
Conditions
As the registry lists them; a condition with its own page is linked.
treatment-resistant schizophrenia